Clinical trial
A Multicentre, Phase 3, Clinical Study to Compare the Striatal Uptake of a Dopamine Transporter Radioligand, DaTSCAN™ Ioflupane (123I) Injection, After Intravenous Administration to Chinese Patients With a Diagnosis of Parkinson's Disease, Multiple System Atrophy, Progressive Supranuclear Palsy, or Essential Tremor and to Healthy Controls
NCT04193527 is registered in ClinicalTrials.gov with GE Healthcare as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicentre, Phase 3, Clinical Study to Compare the Striatal Uptake of a Dopamine Transporter Radioligand, DaTSCAN™ Ioflupane (123I) Injection, After Intravenous Administration to Chinese Patients With a Diagnosis of Parkinson's Disease, Multiple System Atrophy, Progressive Supranuclear Palsy, or Essential Tremor and to Healthy Controls
- Lead sponsor
- GE Healthcare
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- June 28, 2020
- Completion date
- December 20, 2021
- Enrollment
- 172 (actual)
- Sites
- 10
Conditions
As the registry lists them; a condition with its own page is linked.
essential tremor, multiple system atrophy (msa), parkinson disease(pd), parkinsonian syndrome, progressive supranuclear palsy (psp)